Biogen (BIIB) Tops Q4 EPS by 3c; offers outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $253.52 +1.84%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $3.44, $0.03 better than the analyst estimate of $3.41. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.41 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $15.25-$16.25, versus the consensus of $16.24.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
